Recent studies have shown that postmenopausal follicle-stimulating hormone (FSH) may be inversely associated with prevalence of metabolic syndrome, diabetes and atherosclerosis in postmenopausal women [1–9]. Here, BRD2 is linked to metabolic syndrome.